RESTON, Va., Aug. 31, 2017 /PRNewswire/ -- Leidos (NYSE: LDOS), a FORTUNE 500® science and technology company, was awarded a prime contract by the U.S. Army Medical Research Acquisition Activity to provide scientific and administrative services to the Congressionally Directed Medical Research Programs (CDMRP). The single-award, indefinite delivery/indefinite quantity, cost-plus fixed-fee contract has a one-year base ordering period, four one-year optional ordering periods, and a total contract ceiling value of approximately $98 million (inclusive of options). Work will be performed in Frederick, Md.
The CDMRP originated via a Congressional appropriation to foster novel approaches to biomedical research in response to the expressed needs of its stakeholders-the American public, the military, and Congress. The CDMRP manage appropriations annually totaling over $1 billion for intramural and extramural programs directed toward targeted medical research initiatives. For more than 25 years, Leidos has supported the process with innovative solutions to programmatic review of all research applications.
Under the contract Leidos will leverage its expertise and knowledge of the program to provide scientific and administrative support to Leadership and Government Program Managers, including establishing and managing the Programmatic Panels to advise the government on potential applications for research funding.
"We look forward to continuing to support the CDMRP with an established and respected process for reviewing research applications to further medical research initiatives that contribute to protecting the health of our soldiers," said Leidos Group President Jon Scholl.
Leidos is a Fortune 500® science and technology solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company's 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended December 30, 2016, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.